Recombinant viral-like particles of parvovirus B19 as antigen carriers of anthrax protective antigen.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  In Vivo

• Publication date

  2006-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 16724664
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1.

  2003cited by this paper
• Alanine-scanning Mutations in Domain 4 of Anthrax Toxin Protective Antigen Reveal Residues Important for Binding to the Cellular Receptor and to a Neutralizing Monoclonal Antibody*

  2003cited by this paper
• A Recombinant Carboxy-Terminal Domain of the Protective Antigen of Bacillus anthracis Protects Mice against Anthrax Infection

  2002cited by this paper
• Development of an improved vaccine for anthrax.

  2002cited by this paper
• Search for Correlates of Protective Immunity Conferred by Anthrax Vaccine

  2001cited by this paper
• Identification of the cellular receptor for anthrax toxin

  2001cited by this paper
• Priming of Strong, Broad, and Long-Lived HIV Type 1 p55gag-Specific CD8+ Cytotoxic T Cells after Administration of a Virus-Like Particle Vaccine in Rhesus Macaques

  2000cited by this paper
• The comprehensive sourcebook of bacterial protein toxins

  1999cited by this paper
• Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax.

  1999cited by this paper
• Oligomerization of anthrax toxin protective antigen and binding of lethal factor during endocytic uptake into mammalian cells.

  1999cited by this paper
• Identification of a Receptor-Binding Region within Domain 4 of the Protective Antigen Component of Anthrax Toxin

  1999cited by this paper
• De novo design and structural characterization of proteins and metalloproteins.

  1999cited by this paper
• Parvovirus-like particles as vaccine vectors.

  1999cited by this paper
• Intranasal Delivery of Recombinant Parvovirus-Like Particles Elicits Cytotoxic T-Cell and Neutralizing Antibody Responses

  1999cited by this paper
• A recombinant virus‐like particle system derived from parvovirus as an efficient antigen carrier to elicit a polarized Th1 immune response without adjuvant

  1998cited by this paper
• Crystal structure of the anthrax toxin protective antigen

  1997cited by this paper
• Human Parvovirus B19 Epidemiology and Clinical Manifestations

  1997cited by this paper
• Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells.

  1997cited by this paper
• Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies.

  1996cited by this paper
• Formation of empty B19 parvovirus capsids by the truncated minor capsid protein

  1994cited by this paper
• Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin.

  1992cited by this paper
• Self-assembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions.

  1991cited by this paper
• Immune response to B19 parvovirus and an antibody defect in persistent viral infection.

  1989cited by this paper
• Field Evaluation of a Human Anthrax Vaccine.

  1962cited by this paper

• Protein Nanocages as Building Blocks for Conjugated Supramolecular Materials Displaying Multitasking Properties

  2025cites this paper
• Therapeutic Potential of Engineered Virus-like Particles of Parvovirus B19

  2023cites this paper
• Pandemic and Vaccines – The Case of Deadly Anthrax Infection, Vaccine Development and Evolution

  2020cites this paper
• Therapy with multi-epitope virus-like particles of B19 parvovirus reduce tumor growth and lung metastasis in an aggressive breast cancer mouse model.

  2019cites this paper
• Peptide presentation on primate erythroparvovirus 1 virus-like particles: In vitro assembly, stability and immunological properties.

  2016cites this paper
• Human Parvoviruses

  2016cites this paper
• In Vitro Encapsulation of Heterologous dsDNA Into Human Parvovirus B19 Virus-Like Particles

  2015cites this paper
• Design and Testing of Novel Anthrax Vaccines Utilizing a Tobacco Mosaic Virus Expression System

  2015cites this paper
• The application of virus-like particles as vaccines and biological vehicles

  2015cites this paper
• Anthrax vaccines: present status and future prospects

  2013cites this paper
• Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures

  2013cites this paper
• Development and characterization of artificial viruses for gene therapy

  2013cites this paper
• Engineered Biological Entities for Drug Delivery and Gene Therapy

  2011cites this paper
• Induction of mucosal immunity using virus-like particle based vaccines

  2011cites this paper
• Kinetic Investigations of Thiolate Protected Gold Nanoparticles: Protein Interactions, Electron Transfer, and Precursor Formation

  2011cites this paper
• The public acceptance of nanomedicine: a personal perspective.

  2009cites this paper
• Nanoparticle-based biologic mimetics.

  2009cites this paper
• Virus-like particles: flexible platforms for vaccine development

  2007cites this paper
• Proteasome-Independent Major Histocompatibility Complex Class I Cross-Presentation Mediated by Papaya Mosaic Virus-Like Particles Leads to Expansion of Specific Human T Cells

  2006cites this paper